

Enteric and systemic postprandial lactate shuttle phases and dietary carbohydrate carbon flow in humans

Received: 22 June 2023

Accepted: 24 January 2024

Published online: 22 February 2024

 Check for updates

Robert G. Leija¹, Casey C. Curl¹, Jose A. Arevalo¹ , Adam D. Osmond¹, Justin J. Duong¹, Melvin J. Huie¹, Umesh Masharani² & George A. Brooks¹  

Dietary glucose in excess is stored in the liver in the form of glycogen. As opposed to direct conversion of glucose into glycogen, the hypothesis of the postprandial lactate shuttle (PLS) proposes that dietary glucose uptake is metabolized to lactate in the gut, thereby being transferred to the liver for glycogen storage. In the present study, we provide evidence of a PLS in young healthy men and women. Overnight fasted participants underwent an oral glucose tolerance test, and arterialized lactate concentration and rate of appearance were determined. The concentration of lactate in the blood rose before the concentration of glucose, thus providing evidence of an enteric PLS. Secondary increments in the concentration of lactate in the blood and its rate of appearance coincided with those of glucose, which indicates the presence of a larger, secondary, systemic PLS phase driven by hepatic glucose release. The present study challenges the notion that lactate production is the result of hypoxia in skeletal muscles, because our work indicates that glycolysis proceeds to lactate in fully aerobic tissues and dietary carbohydrate is processed via lactate shuttling. Our study proposes that, in humans, lactate is a major vehicle for carbohydrate carbon distribution and metabolism.

The history of discoveries on the pathway of carbohydrate disposal can be traced to studies of isolated amphibian muscles studied without circulation or oxygenation^{1–4}. Thinking around the process and regulation of glycolysis and the resulting cloud of understanding about aerobic and anaerobic processes can be traced to the same set of formative discoveries. However, few efforts have been made to understand glycolysis in the gastrointestinal tract after carbohydrate nutrition. Previously, based on rodent experimentation we posited the presence of a PLS⁵, but little experimental support was available in humans. Evidence supporting the presence of a PLS included: the ‘glucose paradox’ or ‘indirect pathway of hepatic glycogen synthesis’⁶, postprandial lactate production in rat muscle after a glucose challenge^{7,8} and portoperipheral lactate gradients in rats given an intestinal glucose load⁹. In

aggregate, those results indicate lactate production in the intestinal lumen or wall and systemic lactate production after an oral glucose challenge. We sought to test for the presence of a PLS in humans using an oral glucose tolerance test (OGTT), primed continuous infusion (CI) of glucose and lactate tracers and ‘arterialized’, warmed hand vein blood sampling; the presence of enteric and systemic PLS phases is indicated.

Volunteers could be classified as healthy, physically active young men and women (Supplementary Table 1), but not athletes in training^{10,11}. Insulin and glucagon responses are shown in Fig. 1a,b, respectively. In the figures, time zero represents an average of 75- and 90-min values after initiation of isotope tracer infusion. The 5-min and subsequent time points represent time after consumption of 75 g of D-glucose (that is, post-challenge). In the present study, we provide mean \pm s.d. for

¹Exercise Physiology Laboratory, Department of Integrative Biology, University of California, Berkeley, CA, USA. ²Department of Medicine, University of California, San Francisco, CA, USA. ✉e-mail: gbrooks@berkeley.edu




Fig. 1 | Concentrations of plasma insulin, glucagon, blood glucose and lactate in relation to the OGTT. Arterial [lactate] and insulin rise before glucose rises and glucagon falls. a–d, Plasma insulin (a) and glucagon (b), blood glucose (c) and lactate (d) concentrations before, during and after an OGTT. Values are

mean \pm s.d. *Significantly changed from baseline, pre-OGTT levels ($P < 0.05$). A two-tailed ANOVA with corrections for repeated comparisons using Dunnett's tests was employed. The statistical significance for group differences was determined at $\alpha = 0.05$.

the volunteers studied. Consistent with previous observations, insulin rose and glucagon fell in response to an OGTT ($P < 0.05$). It is interesting that there was a rapid, significant post-challenge rise in insulin at 5 min that preceded the fall in glucagon or the rise in arterialised blood [glucose] ($P < 0.05$).

Arterialised blood glucose and lactate concentrations are presented in Fig. 1c,d, respectively. From baseline blood [glucose] was significantly elevated at 15 min ($P < 0.05$) and peaked 60 min after the oral challenge ($P < 0.05$). In contrast, blood lactate concentrations rose from baseline within 5 min ($P < 0.05$); arterial [lactate] peaked at 15 min post-consumption ($P < 0.05$). Immediately after the spike in blood [lactate], we observed a significant decline at 30 min post-challenge ($P < 0.001$). The nadir in blood [lactate] at 30 min was followed by a steady rise above baseline with a second peak at 60 min, after which [lactate] remained elevated ($P < 0.05$).

The arterial lactate:pyruvate ratio (L:P) was nominally 10 before the oral glucose challenge, rose to 20 by 15 min after the glucose challenge and remained ≥ 10 for the duration of observations ($P < 0.05$). Changes in the L:P were mainly the result of changes in [lactate], not [pyruvate] (Extended Data Fig. 1a,b). Isotopic enrichments (IEs) of pyruvate approximated half those of lactate and IEs of alanine approximated one-fifth of lactate and did not correlate ($r = 0.04$) (Extended Data Fig. 1c).

There were clear differences in blood glucose and lactate kinetics post-glucose challenge. Arterial glucose rate of appearance (Ra) was significantly higher than baseline from 15 min to 120 min post-glucose challenge (Fig. 2a; $P < 0.05$). In contrast, post-challenge blood lactate Ra followed a bimodal pattern featuring an initial rise from pre-OGTT at 5 min and 15 min (Fig. 2b; $P < 0.05$). As with blood [lactate], this initial phase in the lactate Ra response was followed by a nadir at 30 min, with a subsequent steady rise in lactate Ra ($P < 0.05$). Hence, the initial peak in blood [lactate] after an oral glucose challenge (Fig. 1d) was the result of a sudden rise in blood lactate appearance (Fig. 2b). In accordance with these changes, increases in Ra from baseline to 5 min

post-glucose challenge were significantly greater for lactate than for glucose ($P < 0.05$) (Fig. 2c).

Lactate oxidation rates rose significantly post-glucose challenge (Fig. 3a). The percentage of lactate disposal via oxidation increased significantly from pre-OGTT ($46 \pm 8\%$) to post-glucose challenge ($57 \pm 8\%$, $P < 0.05$). Owing to increasing systemic PLS phase glucose appearance (Fig. 2a), presumably from hepatic glucose release¹², the percentage of lactate disposed of via gluconeogenesis (GNG) decreased ($P < 0.05$) (Fig. 3b). However, the overall role of GNG in disposal of the initial glucose load increased over time (see below).

First-pass glucose carbon retention by the liver after participants ingested glucose solution was calculated by subtracting the combined appearance amounts of lactate, glucose and glucose-derived lactate from the 75-g glucose load. For the first 30-min post-glucose challenge, we determined appearance amounts to be: 9 g as blood lactate, 3 g as blood glucose that bypassed the liver and 2 g as blood glucose derived from lactate via GNG. Hence, the estimate of glucose absorption converted to glycogen or otherwise retained in the liver during the first, enteric PLS phase was 61 g ($= 75 - 14$ g) (Fig. 4a). For the second systemic PLS phase, and overall, we calculated that the 75-g glucose load was accounted for as follows: 29 g as blood lactate, 24 g of glucose from hepatic glucose release, 8 g of glucose from GNG, with 14 g remaining as hepatic glycogen storage or otherwise unaccounted for (Fig. 4b).

To evaluate the veracity of our estimate of the liver's role in sequestering first-pass dietary glucose uptake, we compared our results to those of Stender et al. who used ¹³C-magnetic resonance spectroscopy (MRS) technology to determine hepatic glucose uptake after a ¹³C-spiked OGTT¹². Coinciding with our proposed enteric PLS phase, the data of Stender et al.¹² indicate that hepatic glucose sequestration was detected as soon as 2 min after the oral glucose challenge, peaked at approximately 25 min and declined thereafter.

We used relatively non-invasive means involving glucose and lactate tracers to interrogate the hypothesis of a PLS in healthy young men and women. We observed that responses of arterialised blood




Fig. 2 | Rates of appearance of glucose and lactate in relation to the OGTT. Glucose was fed but arterial lactate appearance (Ra) rose before glucose Ra. a,b, Glucose and lactate rates of appearance (glucose Ra) (a) and (lactate Ra) (b) before, during and after an OGTT. **c,** Changes in glucose Ra and lactate Ra before and 5 min after glucose challenge. Values are mean \pm s.d. *Significantly increased from baseline ($P < 0.05$). For a and b a two-tailed ANOVA with corrections for repeated comparisons using Dunnett's tests was employed and for c a two-tailed, unpaired Student's *t*-test was applied. G, glucose; L, lactate. The statistical significance for group differences was determined at $\alpha = 0.05$.

[lactate] and appearance rates preceded corresponding changes in [glucose] and furthermore that secondary, incremental changes in blood [lactate] and Ra coincided with those of glucose. Furthermore, for both men and women, we found that the rise in arterial lactate Ra was greater than that of glucose after an oral glucose challenge. Moreover, we found that [insulin] rose before changes in arterialized blood [glucose]. Therefore, we deduce the following: (1) the PLS comprises two components, a first, fast enteric phase of lactate production from gut glycolysis that is followed by a prolonged systemic phase as glucose is disposed of via glycolysis throughout the body corpus; (2) postprandial lactate shuttling is a significant means of managing a dietary carbohydrate carbon challenge; and (3) as arterial insulin rises before glucose, there is also an enteric phase to the insulin response.

We have hypothesized the presence of a PLS⁵ and found evidence for enteric and systemic shuttle phases. Furthermore, we have tested the hypothesis by sampling arterialized blood and measuring lactate and glucose concentrations and kinetics during an OGTT using primed, continuous vascular infusions of D-d₂-glucose and [¹³C]lactate. This combination of tracers also allowed us to determine GNG from lactate. Most importantly, after an oral glucose challenge we saw an immediate rise in both blood lactate Ra and hence in concentrations. Although there was rise in blood glucose Ra 15 min after the glucose challenge, there was a greater change in lactate kinetics than in glucose (Fig. 3c), indicative of rapid enteric glycolytic activity.

To evaluate the veracity of our estimate of the liver's role in sequestering first-pass dietary glucose uptake, we compared our results with those of Stender et al. who used ¹³C-MRS technology to determine hepatic glucose uptake after a ¹³C-spiked OGTT¹². Coinciding with our proposed PLS phase, the data of Stender et al.¹² indicated that hepatic glucose sequestration could be detected as soon as 2 min after the oral glucose challenge, peaked at approximately 25 min and declined thereafter. Stender et al.¹² estimated that first-pass glucose sequestration by the liver accounted for 'most' of the glucose load; our estimate was $82 \pm 2\%$ sequestration (Fig. 4a), the difference attributable to enteric glycolysis producing lactate or glucose that escaped first-pass hepatic sequestration.

In making our calculations we assumed that hepatic glycogenolysis was minimal during the first, enteric PLS phase, but increased later during the subsequent systemic PLS phase. That assumption is justified based on the results of Stender et al.¹² who showed that initial hepatic glucose sequestration, followed by a continuous decline in liver glycogen, presumably gave rise to the blood glucose appearance explaining the continuous rise in glucose Ra during the systemic PLS phase (Figs. 1c and 2a).

In some respects our data on blood lactate flux are consistent with those of Schlicker et al.¹³. However, they made no attempt to account for the liver's role in managing carbon flux. Schlicker and colleagues observed uniformly labelled lactate in blood of men after either a mixed meal or OGTT containing [U-¹³C]glucose. Unfortunately, with regard to the presence of an enteric PLS phase, they did not report blood data soon after delivering the glucose challenge (for example, at 5 min). Moreover, it is unclear where blood sampling occurred; an antecubital venous, as opposed to an arterial sampling site, could be assumed. In addition, without a primed CI, they could not calculate lactate Ra or quantitatively account for distribution of ¹³C in the glucose challenge. Despite these limitations, they showed the presence of systemic lactate shuttling as a metabolic buffer to manage a postprandial carbohydrate load.

Our calculations indicate that, on first portal vein blood pass, the liver sequestered most (82%) of the oral glucose load and that only a small percentage of glucose bypassed the liver and appeared in the blood in the first minute after challenge. However, the delayed increase in glucose Ra over time was subsequently disposed of by conversion to lactate, as illustrated by the continuous systemic phase increase in lactate appearance. In accord with our results Gerich and colleagues also observed that glycolysis accounted for most (two-thirds) of the postprandial glucose disposal and that the majority of post-meal hepatic glycogen synthesis in fasted humans was formed via the direct pathway¹⁴.

The results of our resting, pre-OGTT values of lactate appearance agree well with our previous estimates on healthy young men ($1.8\text{--}2.6 \text{ mg kg}^{-1} \text{ min}^{-1}$)¹⁵⁻¹⁸. In the absence of portal vein catheterization, it is problematic to estimate how much lactate from the glucose load contributed to the initial rise in blood [lactate] and Ra. But, from Fig. 3b, it appears that the rates of appearance of blood lactate increased approximately $0.5 \text{ mg kg}^{-1} \text{ min}^{-1}$; if so, approximately 2% of the glucose load appeared as lactate within 5 min (Fig. 4a). Thereafter, the increase in lactate Ra over pre-OGTT represented 38% of the 75-g




Fig. 3 | Percentage disappearance of and fractional GNG from lactate in relation to the OGTT. A shift in lactate disposal from GNG to oxidation following an OGTT. a,b, Percentage of lactate disappearance disposed of via oxidation (a) and fractional (f) GNG from lactate (b) before and after an OGTT. Values are mean \pm s.d. *Significantly decreased from baseline ($P < 0.05$). A two-tailed, paired Student's t -test was applied. The statistical significance for group differences was determined at $\alpha = 0.05$.

OGTT. Therefore, although the initial spike in the first (enteral) PLS is perhaps a remarkable finding, the majority of lactate production after an oral glucose challenge occurs during the subsequent, second systemic PLS phase.

Compared with arterial [glucose], the rapid rises in blood [lactate], lactate Ra and insulin are most probably attributable to enteric processes. With lactate gaining further attention as a signalling molecule¹⁹, the present results may have revealed the presence of a neuroenteric signalling mechanism (enterokine) or mechanisms in humans. An effect of lactate stimulating sensory nerves associated with mesenteric lymphatic fluid may be a mechanism explaining the rapid response to lactate. Using a rodent model, Aponte and collaborators obtained results consistent with the idea that increased enteric lactate may help facilitate insulin secretion by acting on substance P-containing nerves²⁰. Furthermore, with regard to enteric lactate signalling, the presence of basolateral lactate transporters (that is, monocarboxylate transporter 1 (MCT-1) and -4)^{21–23} may facilitate neuroenteric signalling processes.

It should be noted that carbohydrate partitioning in 12-h postabsorptive, healthy young people raises the arterial L:P from a nominal value of 10 to one of 20. As such, doubling of the circulating L:P represents a significant systemic redox signal^{24–26}. Redox communication via the L:P affects redox status in cytosolic and mitochondrial compartments and, thus, signalling in diverse tissues depending on metabolic




Fig. 4 | Carbon distribution of hepatic glucose and glycogen, blood lactate and glucose and GNG-derived glucose and the oral glucose challenge. Following an OGTT, most glucose-carbon fluxes through the lactate pool. a,b, Account of carbon distribution of hepatic glucose and glycogen, blood lactate, blood glucose and GNG-derived glucose 30 min (a) and 120 min (b) after a 75-g oral glucose challenge.

rate, physiological state and other conditions. Furthermore, beyond redox signalling including sirtuin activation, lactate affects metabolism via allosteric (for example, transforming growth factor- β and lactate receptor HCAR1), protein and histone modifications^{25,27}.

And, finally, it has not escaped our notice that the beneficial effect of metformin on glucose levels in people with diabetes might be via its effect on the PLS. Metformin occurs at higher concentrations in enterocytes compared with the plasma, hence increasing intestinal lactate production after a glucose load²⁸. It is possible that an unrecognized role of metformin is to buffer a glucose load by diverting carbon flow to lactate.

In the present study we focused on the effect of an OGTT on parameters of lactate flux. For that purpose, tracers were introduced into the systemic circulation via an indwelling venous catheter with 'arterialized' blood sampled from a contralateral, warmed hand vein. In retrospect, sampling catheter placement was fortuitous because, from our previous experience, we might not have seen significant rises in systemic blood lactate concentration or Ra had an antecubital sampling site been used. Notwithstanding the interest in assessing the effect in systemic lactate kinetics via an increase in blood [lactate] and decline in isotopic lactate enrichment, an alternative approach would have been to spike the glucose to be consumed with [¹³C]glucose and look for a rise in the systemic [¹³C]lactate signal after the OGTT.

In the study, we employed a standard OGTT that is used experimentally and clinically. Alternatively, we could have ^{13}C spiked a standardized meal tolerance test that would be more relevant to the metabolic consequences of nutrition in daily life. Given the numerous combinations of foods consumed in free-living conditions and the substrate–substrate interactions expected, more research on roles of the gut on energy substrate availability and peripheral disposal will be required to understand the role of a PLS in daily life, health and disease.

In our experiments we had no direct measure of hepatic glucose carbon retention after an oral glucose load, but rather estimated the liver's role from the blood metabolite flux rates determined. In addition, we had no direct measures of muscle glycolysis during the proposed systemic PLS phase. However, ^{13}C -MRS technologies are emerging to test the veracity of assumptions.

And, finally, our methodology did not allow for assessment of the role of the kidneys in managing an oral glucose load; the kidneys probably had a role in GNG from lactate.

Although the current aim of the study was meant to illustrate the enteric production of lactate from glucose, we also observed an immediate rise in insulin concentrations. This rise in insulin within the first 30 min supports our estimates of glycogen storage. Moreover, it may be safe to assume that the total amount of lactate produced from enteric glycolysis after the beverage was underestimated because a fraction of it was probably redirected to the liver and gave rise to glycogen. In aggregate, previous results are entirely consistent with the presence of a second, or systemic, phase to the PLS. And, although postprandial metabolism was not studied by Hui et al.²⁹, their data support the role of lactate as a major means of distributing corporal carbohydrate carbon^{16,30–32}.

Antiquated ideas of peripheral lactate production caused by hypoxia in peripheral muscles must be supplanted, because first glycolysis proceeds to lactate under fully aerobic conditions and second carbohydrates are processed via lactate shuttling. To rephrase, lactate production and signalling are not peripheral events related to exercise and anaerobic glycolysis in working skeletal muscle, but are rather central processes. Lactate is a major vehicle for carbohydrate carbon distribution and metabolism in mammals including humans.

Methods

Subjects

The present study was approved by the University of California Berkeley Committee for the Protection of Human Subjects (CPHS no. 2018-08-11312) and conformed to the standards set by the Declaration of Helsinki. Seven men and eight women aged 21–35 years were recruited via posted notice, newspaper advertisement and social network media. Potential participants were interviewed, and received verbal and written information on study purposes and procedures. After giving verbal and written consent, potential participants were screened for metabolic and cardiovascular diseases (Supplementary Table 1). This involved participants completing a health history questionnaire and 3-d food record forms, and undergoing a blood draw for a basic metabolic panel, ECG and pulmonary function assessments, skinfold measurements, physical examination and $\dot{V}\text{O}_2$ peak and ventilatory threshold assessments. For dietary controls, subjects provided 3-d food records that were analysed for caloric intake and macronutrient composition (DietAnalysis Plus, v.6.1, ESHA Research). Only individuals providing evidence of standard, balanced food records, having benign medical histories, passing physical and physiological assessments, and cleared for participation by a licensed physician were entered into the study. Participants included in the study had a body mass index in the range ≥ 18.5 to $<30 \text{ kg m}^{-2}$ (ref. 33), were non-smokers, had a forced expiratory volume in 1 s/forced vital capacity (FEV_1/FVC) of $>70\%$, were diet and weight stable, and had fasting blood glucose levels $<100 \text{ mg dl}^{-1}$ and glycated haemoglobin (HbA1c) levels $<5.8\%$. To assess physical fitness, subject screening included a continual, progressive, leg-cycle

ergometer test to assess ventilatory threshold (VT) and maximal oxygen consumption (VO_2 peak). Subject screening preceded OGTT testing by at least 1 week. Those entered into the study were provided with verbal and written information on freedom to withdraw from the study, as well as contact information on the laboratory manager, principal investigator and physician should any adverse effects of study procedures occur.

Tracers

As previously, studies involved primed CI of glucose and lactate and a priming dose of ^{13}C bicarbonate^{15,31}. Specifically: $[6,6\text{-}^2\text{H}]\text{glucose}$ ($\text{D-d}_2\text{-glucose}$, M + 2 signal) (labels lost in glycolysis) gives the rate of glycolysis. Priming and CI cocktails were 250 mg and 2 mg min^{-1} , respectively. $[3\text{-}^{13}\text{C}]\text{lactate}$ (label lost in the tricarboxylic acid cycle (TCA) or recycles to glucose in liver and kidneys) gives parameters of lactate production, clearance, oxidation ($^{13}\text{CO}_2$) and GNG (via the Cori cycle, that is, ^{13}C glucose from lactate, M + 1 signal). Priming and CI cocktails were 57.5 mg and 2.5 mg min^{-1} , respectively. $\text{H}^{13}\text{CO}_3^-$ was used to prime the bicarbonate–carbonic acid pool, with a priming dose of 136 mg . The ^{13}C tracers were given as sodium salts. Isotope tracer cocktails, including boluses and CI cocktails, were prepared by Mariner Advanced Pharmacy and Compounding Company.

Procedures

The day before the OGTT, the subjects were asked to record and maintain their standard dietary pattern and refrain from strenuous physical exercise. Women who participated did so during the mid-follicular phase of their cycle. After a 12-h overnight fast, the participants reported to the lab, rested for 90 min followed by a 120-min OGTT which started at 07:00. For this, the research team arrived at 04:30 to set up while the subject arrived at 05:00 for study preparation. A warmed hand vein for arterialized blood sampling was catheterized and a contralateral arm vein was catheterized for tracer infusion. No adverse effects of catheterization and tracer infusion were reported.

After set-up and catheterization, background blood and breath sampling for VO_2 , VCO_2 , respiratory exchange rate ($= \text{VCO}_2/\text{VO}_2$) and $^{13}\text{CO}_2$ occurred, and arterialized blood was taken for determinations of endogenous isotopic enrichments as well as insulin and counter-regulatory hormone levels. Subsequently, priming boluses of $\text{D-d}_2\text{-glucose}$, $[3\text{-}^{13}\text{C}]\text{lactate}$ and $\text{H}^{13}\text{CO}_3^-$ were given and CIs of $\text{D-d}_2\text{-glucose}$ and $[3\text{-}^{13}\text{C}]\text{lactate}$ commenced. A 90-min isotope equilibration period was allowed with simultaneous blood and breath samples taken at 75 and 90 min of the CI^{15,16,31}.

OGTT

After 90 min of CI, the participants drank a solution a 296-ml (10-oz) solution containing 75 g of D-glucose (Azer Scientific, catalogue no. 10-0-75). Most subjects consumed the drink in 1–2 min. After the drink, a 2-h timer was initiated and arterialized blood and expired air were taken for determinations of isotopic enrichments (IEs) and glucoregulatory hormones at 5, 15, 30, 60, 90 and 120 min after the OGTT.

Determinations of IEs

IEs of blood metabolites were as described previously^{10,15–17,31}. Blood samples were immediately placed in 7% perchloric acid after collection and then centrifuged at $3,000g$ for 10 min at 4°C . The clear supernatants were then collected and used for analysis. Samples were then neutralized with 2 M KOH and transferred to ion exchange columns that were previously washed with double deionized water (ddH_2O) through a cation resin (Analytical Grade 50W-X8, 50- to 100-mesh H^+ resin, BioRad Laboratories) and with ddH_2O followed by 2 M formic acid through an anion resin (Analytical Grade 1-X8, 100–200 mesh formate resin). Lactate was eluted through the anion column with 2 M formic acid. The samples were then transferred to a 2-ml gas chromatography vial and lyophilized.

For lactate, samples were resuspended in 200 μl of 2,2-dimethoxypropane and transferred to a vial to which 20 μl of 10% HCl in methanol was added. After samples sat at room temperature for 60 min, 50 μl of *N*-propylamine was added. Samples were then heated for 30 min at 100 °C and subsequently dried under a stream of N_2 gas, resuspended in 200 μl of ethyl acetate, transferred to a gas chromatography–mass spectrometry (GC–MS) vial and dried again under N_2 gas, resuspended in 20 μl of heptafluorobutyric anhydride, left for 5 min at room temperature to react and dried under N_2 gas. Finally, the derivatized lactate was resuspended in 50 μl of ethyl acetate.

For pyruvate, IEs and concentrations were measured via GC–MS of the trimethylsilyl-quinoxalinol derivative. As described previously³⁴ with slight modifications, 300 μl of perchloric acid extracts were spiked with an internal standard of α -ketovalerate and mixed with 4 M HCl + 4% *o*-phenylenediamine solution (1:1). The solution was heated for 60 min at 90 °C, allowed to cool to room temperature and subsequently extracted using 2.4 ml of methylene chloride. The aqueous layer was removed and the remaining solution was dried under a gentle stream of N_2 . Next, 75 μl of pyridine and 75 μl of *N,O*-bis(trimethylsilyl) trifluoroacetamide (BSTFA + 1% trimethylchlorosilane (TMCS)) were mixed and directly added to the dried residue. For alanine IEs, these procedures were repeated to obtain *N,O*-bis(trimethylsilyl)alanine.

For glucose, 200 μl of whole blood was placed in 400 μl of ethanol and spun at 10,000g for 1 min. A liquid-to-liquid ethanol extraction was performed and the organic layer containing glucose was extracted and transferred to a 2-ml glass vial and dried under N_2 gas. The dried glucose was derivatized using 100 μl of a 2:1 mixture of acetic anhydride and pyridine. The GC vial was sealed and heated at 60 °C for 20 min. After 20 min, the sample was dried under N_2 then reconstituted in 100–500 μl of ethyl acetate.

Lactate LEs were determined by GC–MS (GC model 6890 series and MS model 5973N, Agilent Technologies). Methane was used for chemical ionization with selected ion monitoring of mass-to-charge ratios (*m/z*) 328 (non-labelled lactate) and 329 (M + 1 isotopomer, [$3\text{-}^{13}\text{C}$]lactate). Whole-blood lactate concentrations were determined enzymatically³⁵.

Pyruvate LEs were determined by GC–MS on a DB-1701 column of 30 m \times 0.25 μm \times 0.25 m. Methane was used for chemical ionization with selected ion monitoring of *m/z* 233 (non-labelled pyruvate), 234 (M + 1 isotopomer, [$3\text{-}^{13}\text{C}$]pyruvate) and 261 (α -ketovalerate). Similarly, samples were reinjected and analysed for alanine IEs utilizing 219 (non-labelled alanine) and 220 (M + 1 isotopomer, [$3\text{-}^{13}\text{C}$]alanine).

Glucose LEs were determined by GC–MS utilizing positive chemical ionization and selected ion monitoring on a DB-17 GC column. The *m/z* ratios of 331 (non-labelled glucose), 332 (M + 1 isotopomer, [$1\text{-}^{13}\text{C}$]glucose) and 333 (M + 2 isotopomer, D- d_2 -glucose) were monitored for the glucose penta-acetate derivative. Whole-blood glucose concentrations were determined enzymatically³⁶. Selected ion abundances were compared against external standard curves for calculation of the IEs.

The expired air samples were stored at room temperature until analysed via isotope ratio MS by the University of California, Davis Stable Isotope Facility (Davis, CA).

Calculations

Lactate and glucose flux rates, that is, rate of appearance (Ra, $\text{mg kg}^{-1} \text{min}^{-1}$), rate of disposal (Rd, $\text{mg kg}^{-1} \text{min}^{-1}$) and metabolic clearance rate (MCR, $\text{ml kg}^{-1} \text{min}^{-1}$) were calculated from the equations of Steele modified for use with stable isotopes³⁷:

$$\text{Ra} = \frac{F \cdot V \left(\frac{C_1 + C_2}{2} \right) \left(\frac{\text{IE}_2 - \text{IE}_1}{t_2 - t_1} \right)}{\left(\frac{\text{IE}_1 + \text{IE}_2}{2} \right)} \quad (1)$$

$$\text{Rd} = \text{Ra} - V \left(\frac{C_2 - C_1}{t_2 - t_1} \right) \quad (2)$$

$$\% \text{ lactate Rd oxidized} = \frac{(\text{IECO}_2 \times \dot{V}\text{CO}_2 \times 90.08)}{(F \times k \times 22.4)} \times 100 \quad (3)$$

$$\text{Total lactate } R_{\text{ox}} = \frac{(\text{Lactate Rd} \times \% \text{ lactate Rd oxidized})}{100} \quad (4)$$

where *F* represents isotope infusion rate ($\text{mg kg}^{-1} \text{min}^{-1}$), *V* is the volume of distribution for glucose and lactate (180 ml kg^{-1}), *C*₁ and *C*₂ are concentrations (mg l^{-1}) at sampling times *t*₁ and *t*₂, respectively, and IE₁ and IE₂ are the excess IEs of lactate at these sampling times. IE_{CO₂} is the excess IE of expired $^{13}\text{CO}_2$, $\dot{V}\text{CO}_2$ is in l min^{-1} , 90.08 is the molecular mass of [$3\text{-}^{13}\text{C}$]lactate, *F* is the [$3\text{-}^{13}\text{C}$]lactate infusion rate in $\text{mg kg}^{-1} \text{min}^{-1}$, *k* is the correction factor for the retention of CO_2 in body pools, as determined previously³⁸ to be 0.83 at rest and 22.4 is the molar volume of CO_2 , a non-ideal gas under standard temperature and pressure conditions.

The percentage of glucose Ra from lactate-derived GNG (%GNG) was calculated as previously described³⁹. This approach was derived from that of Zilversmit et al.⁴⁰:

$$\begin{aligned} & \text{Rate of lactate conversion to glucose} \\ & = \text{GNG} = \frac{(\text{Lactate Ra} \times (\text{Glucose M} + \text{IE}))}{(\text{IE}_{\text{Lac}})} \times H \end{aligned} \quad (5)$$

where glucose M + 1IE is the IE of the M + 1 glucose isotopomer, lactate IE is the IE of lactate and *H* is the Hetenyi factor to correct for loss of label in the TCA during GNG (1.45 at rest and 1.0 during the OGTT^{32,41}). The rate of lactate conversion to glucose was calculated as previously described^{42–45} where the M + 1IE is the IE of the M + 1 glucose isotopomer, lactate IE is the IE of lactate and *H* is the Hetenyi factor.

$$\text{Glucose production from lactate (\%)} = \text{fGNG} = \frac{(\text{GNG})}{(\text{Glucose Ra})} \times 100 \quad (6)$$

Estimation of glucose-to-lactate conversion

Subjects were 12-h fasted and consequently GNG and hepatic glycogenolysis were assumed to be active in supporting blood glucose before the oral glucose challenge. Hence, for estimation of glucose-to-lactate conversion after the OGTT, the 75- to 90-min tracer equilibration period before the OGTT was taken as baseline. Furthermore, it was assumed that, after the OGTT, hepatic glycogenolysis was suppressed such that the insulin concentrations rose and lactate Ra equalled the Glu-to-Lac conversion. Values for enteric and systemic PLS phases and total Glu \rightarrow Lac appear in Fig. 4a,b.

$$\text{Glu} \rightarrow \text{Lac (g)} = \text{Lac Ra} \quad (7)$$

Estimations of direct glucose-to-hepatic glycogen conversion

Estimations were based on the assumption that hepatic glycogenolysis was diminished for the first 30 min after the glucose challenge. This assumption was based on Fig. 3a,b as well as the report of Stender et al. using MRS technology¹². Hence, direct hepatic glycogen synthesis in grams and percentage of the glucose load conversion to hepatic glycogen were computed as:

$$\begin{aligned} & \text{Enteric (30 min) hepatic glycogen content (g)} \\ & = 75 - [(\text{Lactate Ra (g)} + \text{Glucose Ra (g)} + \text{GNG (g)})] \end{aligned} \quad (8)$$

$$\begin{aligned} & \text{2-h hepatic glycogen content (g)} \\ & = 75 - [(\text{Lactate Ra (g)} + \text{Glucose Ra (g)} + \text{GNG (g)})] \end{aligned} \quad (9)$$

Determinations of insulin and glucagon

Blood samples for the determination of plasma hormone concentrations were collected in tubes containing EDTA and protease inhibitors (aprotinin and a dipeptidyl peptidase 4 inhibitor). Concentrations of plasma insulin and glucagon were determined using commercially available ELISA kits (ALPCO).

Statistical analyses

Analyses were performed using GraphPad Prism v.3.0 software. Group sample sizes were predicted based on power analyses using results of our previous studies^{16,30–32}. For comparisons across multiple time points, two-tailed, one-way analysis of variance (ANOVA) was employed, with corrections for repeated comparisons using Dunnett's tests. For comparisons at two single time points, a two-tailed, paired Student's *t*-test was applied. The statistical significance for group differences was determined at $\alpha = 0.05$. Data collection and analysis were performed blind to subject identities, but not to sex.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Source data for Figs. 1a–d, 2a–c, 3a,b, 4a,b, Supplementary Table 1 and Extended Data Fig. 1a–c are provided with this paper.

References

- Hill, A. V. The heat produced in contracture and muscle tone. *J. Physiol.* **40**, 389–403 (1910).
- Meyerhof, O. Die Energieumwandlungen im Muskel II. Das schicksal der milchsäure in der erholungsperiode des muskels. *Pflug. Arch. fur Gesamt. Physiologie des Menschejen und der Tiere* **182**, 284–317 (1920).
- Hill, A. V. The oxidative removal of lactic acid. *J. Physiol.* **48**, x–xi (1914).
- Meyerhof, O. Die Energieumwandlungen im Muskel III. Kohlenhydrat- und Milchsäureumsatz im Froschmuskel. *Pflug. Arch. fur Gesamt. Physiologie des Menschejen und der Tiere* **185**, 11–32 (1920).
- Brooks, G. A. et al. Lactate in contemporary biology: a phoenix risen. *J. Physiol.* **600**, 1229–1251 (2022).
- Foster, D. W. Banting lecture 1984. From glycogen to—and back. *Diabetes* **33**, 1188–1199 (1984).
- James, D. E., Kraegen, E. W. & Chisholm, D. J. Effects of exercise training on in vivo insulin action in individual tissues of the rat. *J. Clin. Invest.* **76**, 657–666 (1985).
- James, D. E. et al. Intrinsic differences of insulin receptor kinase activity in red and white muscle. *J. Biol. Chem.* **261**, 14939–14944 (1986).
- Smadja, C., Morin, J., Ferre, P. & Girard, J. Metabolic fate of a gastric glucose load in unrestrained rats bearing a portal vein catheter. *Am. J. Physiol.* **254**, E407–E413 (1988).
- Emhoff, C. A. et al. Gluconeogenesis and hepatic glycogenolysis during exercise at the lactate threshold. *J. Appl. Physiol.* **114**, 297–306 (2013).
- San-Millan, I. & Brooks, G. A. Assessment of metabolic flexibility by means of measuring blood lactate, fat, and carbohydrate oxidation responses to exercise in professional endurance athletes and less-fit individuals. *Sports Med.* **48**, 467–479 (2018).
- Stender, S. et al. Assessment of rapid hepatic glycogen synthesis in humans using dynamic ¹³C magnetic resonance spectroscopy. *Hepato. Commun.* **4**, 425–433 (2020).
- Schlicker, L. et al. Systemic lactate acts as a metabolic buffer in humans and prevents nutrient overflow in the postprandial phase. *Front. Nutr.* **9**, 785999 (2022).
- Woerle, H. J. et al. Pathways for glucose disposal after meal ingestion in humans. *Am. J. Physiol. Endocrinol. Metab.* **284**, E716–E725 (2003).
- Messonnier, A. L. et al. Lactate kinetics at the lactate threshold in trained and untrained men. *J. Appl. Physiol.* **114**, 1593–1602 (2013).
- Bergman, B. C. et al. Active muscle and whole body lactate kinetics after endurance training in men. *J. Appl. Physiol.* **87**, 1684–1696 (1999).
- Miller, B. F. et al. Lactate and glucose interactions during rest and exercise in men: effect of exogenous lactate infusion. *J. Physiol.* **544**, 963–975 (2002).
- Mazzeo, R. S., Brooks, G. A., Schoeller, D. A. & Budinger, T. F. Disposal of blood [¹⁻¹³C]lactate in humans during rest and exercise. *J. Appl. Physiol.* **60**, 232–241 (1986).
- Brooks, G. A. et al. Lactate as a myokine and exerkine: drivers and signals of physiology and metabolism. *J. Appl. Physiol.* **134**, 529–548 (2023).
- Mayer, F., Gunawan, A. L., Tso, P. & Aponte, G. W. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves. *Am. J. Physiol. Gastrointest. Liver Physiol.* **319**, G23–G35 (2020).
- Orsenigo, M., Tosco, M., Bazzini, C., Laforenza, U. & Faelli, A. A monocarboxylate transporter MCT1 is located at the basolateral pole of rat jejunum. *Exp. Physiol.* **84**, 1033–1042 (1999).
- Orsenigo, M., Tosco, M., Laforenza, U. & Faelli, A. Facilitated transport of lactate by rat jejunal enterocyte. *J. Membr. Biol.* **158**, 257–264 (1997).
- Tamai, I. et al. Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. *J. Pharm. Pharmacol.* **51**, 1113–1121 (2010).
- Brooks, G. A. et al. Lactate as a major myokine and exerkine. *Nat. Rev. Endocrinol.* **18**, 712 (2022).
- Brooks, G. A. et al. Lactate as a myokine and exerkine: drivers and signals of physiology and metabolism. *J. Appl. Physiol.* **134**, 529–548 (2023).
- Corkey, B. E. & Deeney, J. T. The redox communication network as a regulator of metabolism. *Front. Physiol.* **11**, 567796 (2020).
- Galle, E. et al. H3K18 lactylation marks tissue-specific active enhancers. *Genome Biol.* **23**, 207 (2022).
- McCraith, L. J., Bailey, C. J. & Pearson, E. R. Metformin and the gastrointestinal tract. *Diabetologia* **59**, 426–435 (2016).
- Hui, S. et al. Glucose feeds the TCA cycle via circulating lactate. *Nature* **551**, 115–118 (2017).
- Brooks, G. A. The science and translation of lactate shuttle theory. *Cell Metab.* **27**, 757–785 (2018).
- Bergman, B. C. et al. Muscle net glucose uptake and glucose kinetics after endurance training in men. *Am. J. Physiol.* **277**, E81–E92 (1999).
- Bergman, B. C. et al. Endurance training increases gluconeogenesis during rest and exercise in men. *Am. J. Physiol. Endocrinol. Metab.* **278**, E244–E251 (2000).
- Kowalchuk, J. M. et al. Role of lungs and inactive muscle in acid-base control after maximal exercise. *J. Appl. Physiol.* **65**, 2090–2096 (1988).
- Henderson, G. C. et al. Pyruvate shuttling during rest and exercise before and after endurance training in men. *J. Appl. Physiol.* **97**, 317–325 (2004).
- Hohorst, H. J. in *Methods of Enzymatic Analysis* (ed. Bergmeyer, H.-U.) 266–270 (Verlag Chemie and Academic Press, 1965).
- Bergmeyer, H.-U. (ed.) *Methods of Enzymatic Analysis* (Verlag Chemie and Academic Press, 1965).
- Wolfe, R. R. *Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis* (Wiley-Liss, 1992).

38. Henderson, G. C., Horning, M. A., Wallis, G. A. & Brooks, G. A. Pyruvate metabolism in working human skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* **292**, E366 (2007).
39. Huie, M. J., Casazza, G. A., Horning, M. A. & Brooks, G. A. Smoking increases conversion of lactate to glucose during submaximal exercise. *J. Appl. Physiol.* **80**, 1554–1559 (1996).
40. Zilversmit, D. B., Entenman, C. & Fishler, M. C. On the calculation of ‘turnover time’ and ‘turnover rate’ from experiments involving the use of labeling agents. *J. Gen. Physiol.* **26**, 325–331 (1943).
41. Hetenyi, G. Jr & Ferrarotto, C. Correction for metabolic exchange in the calculation of the rate of gluconeogenesis in rats. *Biochem. Med.* **29**, 372–378 (1983).
42. Huie, M., Casazza, G. A., Horning, M. A. & Brooks, G. A. Smoking increases conversion of lactate to glucose during submaximal exercise. *J. Appl. Physiol.* **80**, 1554–1559 (1996).
43. Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* **22**, 1462–1470 (1999).
44. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **28**, 412–419 (1985).
45. Tara, M. W., Jonathan, C. L. & David, R. M. Use and abuse of HOMA modeling. *Diabetes Care* **27**, 1487–1495 (2004).

Acknowledgements

This work was supported by a National Institutes of Health grant no. R01 AG059715-01 to G.A.B. We thank the study participants for their time, efforts and experimental discomfort. In addition, we thank our outstanding research nurses, B. Abungan and W. Walker, and M. A. Horning for advice on GC–MS technology. We thank R. Agostini for advice and support and our exceptional undergrad research apprentices who played an essential role: L. Artenagaara, H. Avalos, J. Brown, K. Lee, Q. Li, N. Talebizadeh, A. Truong, S. Uuganbayar, V. Wat, E. Yang and C. Zhu.

Author contributions

G.A.B. conceived the original hypothesis, participated in experimentation and helped draft the manuscript. R.G.L. participated in all aspects of the investigation, data collection and sample analysis, statistical analysis, writing and editing the manuscript, and responding to the comments of the editor and reviewers. C.C.C., A.D.O. and J.J.D. participated in data collection, sample analysis, and writing and editing the manuscript. J.A.A. participated in sample analysis, and writing and editing the manuscript. M.J.H. participated

in data collection and editing the manuscript. U.M. participated in experimental design, sample analysis, and writing and editing the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s42255-024-00993-1>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s42255-024-00993-1>.

Correspondence and requests for materials should be addressed to George A. Brooks.


Peer review information *Nature Metabolism* thanks Karsten Hiller, Avital Schurr and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Alfredo Giménez-Cassina, in collaboration with the *Nature Metabolism* team.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024



Extended Data Fig. 1 | Time course of blood pyruvate concentrations (A) the lactate to pyruvate ratio (L/P) (B) and isotopic enrichments of lactate, pyruvate, and alanine (C) before, during and after an oral glucose tolerance test (OGTT). Values are means SD. *Significantly increased from baseline

($p < 0.05$). For Fig. 1a, b a two-tailed, one-way analyses of variance (ANOVA) with corrections for repeated comparisons using Dunnett's tests. Statistical significance for group differences was determined at $\alpha = 0.05$.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a | Confirmed |
|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A description of all covariates tested |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	self declared
Reporting on race, ethnicity, or other socially relevant groupings	Not asked or recorded
Population characteristics	Tabled Tabled (Supplemental Table 1)
Recruitment	Posted notice, social media, newspaper and newsletter
Ethics oversight	UCB CPHS Protocol 2018-08-11312

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	15
Data exclusions	CVD or CMD
Replication	NA
Randomization	NA
Blinding	NA

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	NA
Research sample	<i>State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.</i>
Sampling strategy	<i>Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.</i>
Data collection	<i>Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.</i>
Timing	<i>Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.</i>
Data exclusions	<i>If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.</i>

Non-participation	State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.
Randomization	If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	NA
Research sample	Describe the research sample (e.g. a group of tagged <i>Passer domesticus</i> , all <i>Stenocereus thurberi</i> within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.
Sampling strategy	Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Data collection	Describe the data collection procedure, including who recorded the data and how.
Timing and spatial scale	Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Reproducibility	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Randomization	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.
Blinding	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Did the study involve field work? Yes No

Field work, collection and transport

Field conditions	Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).
Location	State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).
Access & import/export	Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).
Disturbance	Describe any disturbance caused by the study and how it was minimized.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- n/a Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Clinical data
- Dual use research of concern
- Plants

Methods

- n/a Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging

Antibodies

Antibodies used

None

Validation

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer's website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

NA

Authentication

Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

Mycoplasma contamination

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Commonly misidentified lines
(See [ICLAC](#) register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Palaeontology and Archaeology

Specimen provenance

DA

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

None

Wild animals

Provide details on animals observed in or captured in the field; report species and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

Reporting on sex

Indicate if findings apply to only one sex; describe whether sex was considered in study design, methods used for assigning sex. Provide data disaggregated for sex where this information has been collected in the source data as appropriate; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex-based analyses where performed, justify reasons for lack of sex-based analysis.

Field-collected samples

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration

NA

Study protocol

Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection

Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes

Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

- | No | Yes |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Public health |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> National security |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Crops and/or livestock |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Ecosystems |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Any other significant area |

Experiments of concern

Does the work involve any of these experiments of concern:

- | No | Yes |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Demonstrate how to render a vaccine ineffective |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Confer resistance to therapeutically useful antibiotics or antiviral agents |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Enhance the virulence of a pathogen or render a nonpathogen virulent |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Increase transmissibility of a pathogen |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Alter the host range of a pathogen |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Enable evasion of diagnostic/detection modalities |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Enable the weaponization of a biological agent or toxin |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Any other potentially harmful combination of experiments and agents |

Plants

Seed stocks	None
Novel plant genotypes	<i>Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.</i>
Authentication	<i>Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.</i>

ChIP-seq

Data deposition

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	NA
Files in database submission	<i>Provide a list of all files available in the database submission.</i>
Genome browser session (e.g. UCSC)	<i>Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.</i>

Methodology

Replicates	<i>Describe the experimental replicates, specifying number, type and replicate agreement.</i>
Sequencing depth	<i>Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.</i>
Antibodies	<i>Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.</i>
Peak calling parameters	<i>Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.</i>
Data quality	<i>Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.</i>
Software	<i>Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.</i>

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	NA
Instrument	<i>Identify the instrument used for data collection, specifying make and model number.</i>
Software	<i>Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.</i>

Cell population abundance

Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.

Gating strategy

Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type

NA

Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition

Imaging type(s)

Specify: functional, structural, diffusion, perfusion.

Field strength

Specify in Tesla

Sequence & imaging parameters

Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.

Area of acquisition

State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.

Diffusion MRI

 Used Not used

Preprocessing

Preprocessing software

Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).

Normalization

If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

Normalization template

Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.

Noise and artifact removal

Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).

Volume censoring

Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

Statistical modeling & inference

Model type and settings

Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).

Effect(s) tested

Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

Specify type of analysis: Whole brain ROI-based Both

Statistic type for inference

Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.

(See [Eklund et al. 2016](#))

Correction

Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).

Models & analysis

- | | |
|-------------------------------------|---|
| n/a | Involvement in the study |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Functional and/or effective connectivity |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Graph analysis |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Multivariate modeling or predictive analysis |

Functional and/or effective connectivity

Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).

Graph analysis

Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).

Multivariate modeling and predictive analysis

Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.